Oncternal Therapeutics, Inc. (ONCT) Stock Price Soared By A Staggering 13.13%. Here’s What Happened.
Oncternal Therapeutics, Inc. (ONCT), a clinical-stage biopharmaceutical company specializing in manufacturing unique oncology therapies, announced the latest interim clinical data from the ongoing Phase 1/2 CIRLL (Cirmtuzumab and Ibrutinib targeting ROR1 for Leukemia and Lymphoma) clinical trial, to be presented at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting. At last check in […]
Why Early Trades Are Soaring For Oncternal Therapeutics (ONCT) Stock Today?
The clinical-stage biopharmaceutical company Oncternal Therapeutics, Inc. (Nasdaq: ONCT) stock is up +4.49% in the early trades today rising to $7.91 as of the writing. Although there has not been any news that could cause the ONCT stock to surge the increase in price could be attributed to the announcement of financial results unveiled by […]